세계의 홍역, 볼거리, 풍진 백신 시장

The Global Measles, Mumps, and Rubella (MMR) Vaccine Market was valued at USD 1.87 billion in 2024 and is projected to reach USD 3.04 billion by 2030, growing at a CAGR of 8.42% during the forecast period. Market growth is being fueled by increasing demand for immunization as a fundamental public health measure. The inclusion of MMR vaccines in national immunization schedules, bolstered by support from international agencies such as WHO and UNICEF, has led to widespread adoption in both high- and low-income countries. Recurring outbreaks of measles, especially in underserved populations, highlight the need for large-scale vaccination campaigns. Strengthening healthcare infrastructure, public-private partnerships, and improved distribution logistics are further enhancing vaccine access and coverage.

Innovation in vaccine delivery methods, including thermostable and needle-free formulations, is also driving growth, particularly in resource-constrained settings. The trend of combining MMR with other pediatric vaccines into a single-dose format is simplifying immunization schedules and improving adherence. Integration with digital health systems is aiding in tracking vaccination coverage and follow-ups, enhancing program efficiency.

Key Market Drivers

Increasing Government Immunization Initiatives

Government-led immunization initiatives have become a pivotal factor driving the global MMR vaccine market. Countries worldwide are prioritizing vaccine-preventable disease control by integrating MMR into routine childhood immunization programs, often at no cost. Increased funding, improved logistics, and targeted rural outreach are elevating vaccine coverage. Supported by organizations such as WHO, UNICEF, and Gavi, these initiatives are reducing disease incidence and mortality, particularly in low-income nations.

Despite such efforts, global immunization coverage still falls short of WHO's 95% target needed for measles elimination. In 2023, only 83% of children globally received the first measles vaccine dose, while just 74% received the second. Alarmingly, over 22 million children missed their first dose. These figures underline the urgency for governments to scale up immunization efforts through enhanced policies, monitoring, and education, reinforcing sustained demand for MMR vaccines.

Key Market Challenges

Vaccine Hesitancy and Misinformation

Vaccine hesitancy, driven by misinformation and distrust, remains a substantial barrier to broader adoption of MMR vaccines. Persistent myths, such as a link between the MMR vaccine and autism, continue to undermine public confidence despite being scientifically disproven. The proliferation of false information via social media and other platforms exacerbates hesitancy, particularly in communities with limited access to reliable healthcare education.

These attitudes delay or reduce vaccine uptake, leading to disease resurgence and undermining public health goals. Overcoming this issue requires coordinated efforts involving community leaders, healthcare providers, and policymakers to promote accurate information and build trust. Tailored education campaigns and transparent communication strategies will be key to addressing misinformation and improving vaccine acceptance across regions.

Key Market Trends

Integration of MMR Vaccines into Universal Immunization Programs

The increasing integration of MMR vaccines into universal immunization programs is a notable trend supporting market expansion. Governments, with backing from global health bodies, are embedding MMR vaccination within broader public health strategies to improve childhood immunization coverage. These efforts are essential in achieving herd immunity and controlling disease outbreaks.

According to WHO, global measles vaccine coverage remains insufficient, with only 83% of children receiving the first dose and 74% the second in 2023. Nearly 35 million children lacked full protection against measles. These gaps emphasize the need for inclusive immunization strategies. As countries intensify efforts to close these coverage gaps, the demand for reliable MMR vaccines is expected to grow significantly.

Key Market Players

• Merck & Co., Inc.
• GlaxoSmithKline plc
• Pfizer Inc.
• Novartis AG
• Serum Institute of India Pvt. Ltd.
• Panacea Biotec Ltd.
• Takeda Pharmaceutical Company Limited
• Sinovac Biotech Ltd.
• Biological E. Limited
• Emergent BioSolutions Inc.

Report Scope

In this report, the Global Measles, Mumps, Rubella Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Measles, Mumps, Rubella Vaccine Market, By Type:

• Monovalent
• Trivalent (combined MMR)
• Tetravalent

Measles, Mumps, Rubella Vaccine Market, By Targeted Population:

• Infants and Children (9 months to 12 years)
• Adults

Measles, Mumps, Rubella Vaccine Market, By Distribution Channel:

• Hospitals and Healthcare Institutions
• Vaccine Centers and Public Health Clinics
• Pediatric and Private Healthcare Clinics

Measles, Mumps, Rubella Vaccine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Measles, Mumps, Rubella Vaccine Market.

Available Customizations

Global Measles, Mumps, Rubella Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Measles, Mumps, Rubella Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Monovalent, Trivalent (combined MMR), Tetravalent)
  • 5.2.2. By Targeted Population (Infants and children (9 months to 12), Adults)
  • 5.2.3. By Distribution Channel (Hospitals and Healthcare Institutions, Vaccine Centers and Public Health Clinics, Pediatric and Private Healthcare Clinics)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Measles, Mumps, Rubella Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Targeted Population
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Measles, Mumps, Rubella Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Targeted Population
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Mexico Measles, Mumps, Rubella Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Targeted Population
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Canada Measles, Mumps, Rubella Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Targeted Population
      • 6.3.3.2.3. By Distribution Channel

7. Europe Measles, Mumps, Rubella Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Targeted Population
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Targeted Population
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Targeted Population
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Targeted Population
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Targeted Population
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Targeted Population
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Measles, Mumps, Rubella Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Targeted Population
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Targeted Population
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Targeted Population
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. South Korea Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Targeted Population
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Japan Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Targeted Population
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Targeted Population
      • 8.3.5.2.3. By Distribution Channel

9. South America Measles, Mumps, Rubella Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Targeted Population
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Measles, Mumps, Rubella Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Targeted Population
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Measles, Mumps, Rubella Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Targeted Population
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Measles, Mumps, Rubella Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Targeted Population
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Measles, Mumps, Rubella Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Targeted Population
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Measles, Mumps, Rubella Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Targeted Population
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Measles, Mumps, Rubella Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Targeted Population
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Measles, Mumps, Rubella Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Targeted Population
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Merck & Co., Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. GlaxoSmithKline plc
• 14.3. Pfizer Inc.
• 14.4. Novartis AG
• 14.5. Serum Institute of India Pvt. Ltd.
• 14.6. Panacea Biotec Ltd.
• 14.7. Takeda Pharmaceutical Company Limited
• 14.8. Sinovac Biotech Ltd.
• 14.9. Biological E. Limited
• 14.10. Emergent BioSolutions Inc.

15. Strategic Recommendations

16. About Us & Disclaimer